Predictive factors in Capecitabine plus CDDP therapy in patients with HER2 negative advanced gastric cancer.

Trial Profile

Predictive factors in Capecitabine plus CDDP therapy in patients with HER2 negative advanced gastric cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 22 Aug 2012 Planned end date changed from 1 Jul 2013 to 31 Aug 2014 as reported by University Hospital Medical Information Network - Japan.
    • 04 Apr 2012 Planned end date (Jul 2013) added as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top